Wedbush Issues Pessimistic Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price

Posted by Stanley Muller on Aug 5th, 2026

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) had its price objective reduced by equities researchers at Wedbush from $12.00 to $11.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s target price would indicate a potential upside of 167.64% from the stock’s previous close.

A number of other analysts have also issued reports on the company. HC Wainwright started coverage on Larimar Therapeutics in a research report on Thursday, July 2nd. They set a “buy” rating and a $10.00 target price on the stock. Robert W. Baird cut their price target on Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 30th. JPMorgan Chase & Co. began coverage on Larimar Therapeutics in a report on Wednesday, May 27th. They issued an “overweight” rating and a $9.00 price target for the company. Wall Street Zen upgraded Larimar Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Citigroup restated a “buy” rating on shares of Larimar Therapeutics in a report on Tuesday, June 30th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Larimar Therapeutics has an average rating of “Buy” and a consensus price target of $12.57.

Get Our Latest Analysis on Larimar Therapeutics

Larimar Therapeutics Trading Up 3.3%

LRMR opened at $4.11 on Wednesday. The company has a fifty day simple moving average of $3.60 and a 200 day simple moving average of $3.97. The firm has a market cap of $426.95 million, a price-to-earnings ratio of -2.00 and a beta of 0.81. Larimar Therapeutics has a twelve month low of $2.71 and a twelve month high of $6.42.

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.08. On average, analysts forecast that Larimar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Thomas Edward Hamilton acquired 50,000 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was bought at an average cost of $3.34 per share, with a total value of $167,000.00. Following the acquisition, the director directly owned 714,798 shares in the company, valued at approximately $2,387,425.32. The trade was a 7.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Larimar Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of LRMR. AQR Capital Management LLC acquired a new stake in Larimar Therapeutics during the first quarter valued at approximately $241,000. Acadian Asset Management LLC bought a new stake in shares of Larimar Therapeutics in the 1st quarter valued at approximately $113,000. Rhumbline Advisers increased its holdings in shares of Larimar Therapeutics by 15.7% in the 1st quarter. Rhumbline Advisers now owns 65,018 shares of the company’s stock valued at $140,000 after acquiring an additional 8,818 shares during the last quarter. American Century Companies Inc. raised its position in shares of Larimar Therapeutics by 7.8% during the 2nd quarter. American Century Companies Inc. now owns 69,285 shares of the company’s stock valued at $200,000 after acquiring an additional 5,001 shares in the last quarter. Finally, Cerity Partners LLC acquired a new stake in shares of Larimar Therapeutics during the 2nd quarter valued at approximately $636,000. 91.92% of the stock is owned by institutional investors.

About Larimar Therapeutics

(Get Free Report)

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.